Turbare Manufacturing, Conway, AR
Is Turbare Manufacturing an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Turbare Manufacturing in Conway, AR, first registered Jun 23, 2023 and most recently registered Dec 3, 2025. FDA lists its last inspection as May 7, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 10/5/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Conway, AR
- Initial registration
- Jun 23, 2023
- Most recent registration
- Dec 3, 2025
- Last inspection
- May 7, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- N/A
- Action on last inspection
- Response Letter Issued 10/5/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Turbare Manufacturing, Conway, AR, a 503B facility, with 3 listed actions, including 2 Form 483s and 1 warning letter (2025 to 2026).
| Document | |||
|---|---|---|---|
| May 7, 2026 | Amended Form 483 | Amended 483 Issued 05/07/2026 | fda.gov |
| Sep 16, 2025 | Warning letter | Warning Letter (09/16/2025) | fda.gov |
| Jan 24, 2025 | Form 483 | 483 Issued 01/24/2025 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Turbare Manufacturing, Conway, AR (FEI number 3027507354), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jan 24, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3027507354 | 1259059 |
Form 483s FDA has published for this site
- May 7, 2026: Form 483 to Turbare Manufacturing, published Sep 8, 2026. fda.gov
- Jan 24, 2025: Form 483 to Turbare Manufacturing, published Feb 7, 2025. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Jan 24, 2025 to May 7, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 20, 2026 to May 7, 2026: 4 observations
- Firm on the cover
- Turbare Manufacturing, 925 Jeanette Dr, Conway, AR 72032-6651
- FEI number
- 3027507354
- Establishment type on the cover
- Outsourcing facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard, actions page, 503B list
- FDA document
- Read the full 483 (PDF on fda.gov); FDA also posts it as https://www.fda.gov/media/194886/download
Observation 1
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
1A . Your Quality Unit failed to:
a. Ensure the timely implementation of corrective and preventive actions for the observed dried and cracked <Redacted B4> settle plates used for environmental monitoring and then incubated in <Redacted B4> incubator. Please refer to OBSERVATION lB.
b. Conduct adequate root-cause analyses for the ongoing Environmental Monitoring (EM) and Personnel Monitoring (PM) excursions. The Quality unit also failed to perform effectiveness checks on the implemented corrective and preventive actions, as evident by persistent fungal and bacterial recoveries despite implementing corrective actions in the clean room areas. Please refer to OBSERVATION 2 and OBSERVATION 3.
c. Investigate the root cause of visual inspection failure during initial 100% inspection before proceeding to secondary /tertiary inspection of the filled syringes. Please refer to OBSERVATION 4.
d . Evaluate air flow patterns under dynamic conditions in all ISO 5 classified BSC cabinets in the clean room. Please refer to OBSERVATION 3.
AMENDMENT2
1B. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically,
2A. Your firm's environmental monitoring program failed to prevent or adequately address repeated fungal (mold) contamination in ISO Class 7 and ISO Class 8 classified areas within the same cleanroom <Redacted B4> that support aseptic compounding operations conducted in ISO Class 5 Primary Engineering Controls.
The environmental monitoring data collected between July 2025 and April 2026 document at least nineteen (19) separate fungal excursion events across ISO 8 rooms (Rooms <Redacted B4> representing a recurring and unresolved pattern of mold contamination in the classified cleamoom environment supporting aseptic compounding operations.
The following is the list of nineteen (19) documented fungal contamination events in the clean room area:
Investigation#
Date Opened I Date Closed
I Room / ISO Class
CFU Count
Organism(s) Identified
I I I I
AM ENDMENT2
EME-25-0046
2025-07-22 2025-09-09 Room <R edacted B4> ISO 8 I CFU IPericowa sp.
EME-25-0055 2025-07-31 2025-09-11 Rooml ISO8 I CFU (3 total) tladosporium cladosporioides ...
Observation 3
Production personnel were not practicing good sanitation and health habits.
Specifically,
Your firm failed to establish and maintain adequate controls to prevent repeated objectionable Inicroorganism recoveries during personnel monitoring (PM) activities in ISO Class 5 and ISO Class 7 classified areas.
Environmental monitoring records document six (6) personnel monitoring excursion events involving bacterial contamination from personnel gowning samples ( chest, forehead, forearm) and fingertip samples collected between April 2025 and February 2026.
AMENDMENT2
Multiple excursions involved objectionable gram-negative organisms. The assigned root causes were generally insufficient aseptic gowning technique, improper material transfer, cleaning or personnel movement.
The following is the list of six (6) documented contamination events:
Investigation#
Date of Sample
Operator /
Room /ISO Class
CFU Count
Organism(s) Identified
Lot Impacted Units Rejected
Root Cause
Sample Type
Corynebacterium segmentosum Actinomyces oris/naeslundii 'Staphylococcus epidermidis 'Staphylococcus capitis
04162025 <Redacted B4> <Redacted B4>
Ineffective aseptic technique during gowning and personnel movement ...
Observation 4
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
Your firm failed to conduct, or document, an investigation into the root cause of visual inspection failures prior to proceeding with secondary and/or tertiary inspections.
A review of ophthalmic lot visual inspection records spanning from March 2025 through early 2026 identified forty-four (44) lots in which the firm proceeded directly to secondary inspection following a primary visual inspection failure which was characterized by major reject rates exceeding the <Redacted B4> acceptance limit and/or major defects found at the primary AQL stage. There was no documented investigation and root cause analysis into the source and cause of these recurring defect types prior to re inspection.
AMENDMENT2
In addition, 2 lots (0926202S <Redacted B4> and 0101-01-26-0067) proceeded to tertiary inspection after secondary inspection also failed, without a documented investigation of initial 100% visual inspection failed. ...
Inspection Jan 14, 2025 to Jan 24, 2025: 8 observations
- Firm on the cover
- Turbare Manufacturing, 925 Jeanette Dr, Conway, AR 72032-6651
- FEI number
- 3027507354
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.
Specifically,
A) During media fill lot <Redacted B4> your firm recovered mold growth from personnel monitoring results of 1 CFU on the right chest sample. This technician was performing compounding activities in the ISO-5 hood for the media fill. Your firm identified the species of mold, Curvularia intermedia, but did not perform any investigation to determine where the mold originated or evaluate patient safety due to the presence of this mold on your personnel performing repackaging activities. Your firm's routine environmental monitoring procedure states that "Action responses are always triggered for viable samples regardless of CFU count when CFU identified are of any highly pathogenic organisms such as gram-negative rods, coagulase positive Staphlyococcus species, molds, or yeasts.
B) Your firm initiated an investigation into a personnel monitoring result of 1 CFU for fingertip monitoring for lot <Redacted B4>. The result was initially discovered on 11/19/2024. ...
Observation 2
Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release.
Specifically,
Specifically,
Your firms AQL sampling of <Redacted B4> of the batch <Redacted B4> syringes) is not statistically significant. In addition, acceptance criteria is not appropriately applied from AQL results.
Avastin repackaged lot <Redacted B4> expiry 4/18/2025, had two major defects identified, both for particulate matter during AQL sampling out of <Redacted B4> syringes evaluated. Your firm's AQ!., limit for major defects <Redacted B4>. Your firm calculated the AQL hmit against the <Redacted B4> of <Redacted B4> syringes resulting in 0.3% major defects. Two syringes out of <Redacted B4> represents approximately <Redacted B4> major defects in the AQL sample. Your firm passed this AQL result with no investigation or additional product inspection. This batch was released for distribution.
Avastin repackaged lot <Redacted B4> expiry 3/14/2025, failed initial 100% visual inspection and was reinspected. ...
Observation 3
Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Specifically,
The defects contained in the visual inspection qualification kit are not well defined and contain approximately <Redacted B4> defects. Your firm's classification of defects is not scientifically justified. Your firm's critical, major, and minor defect classifications are not defined in any procedure and defects have not been assessed for risk to patient. According to your firm's CEO, the defects for each category are:
Critical: <Redacted B4>, and <Redacted B4> Major, <Redcacted B4> and <Redacted B4> Minor, <Redacted B4>.
Observation 4
Employees engaged in the manufacture and processing of a drug product lack the training and experience required to perform their assigned functions.
Specifically,
1) Qualification of your visual inspectors is deficient, for example:
• The characteristics of the defects within the qualification kit are not well defined. For example, particulate defects are listed as <Redacted B4> or "dark" particulate matter of unknown size and composition. Your firm cannot evaluate the capabilities of visual inspectors without developing a well defined qualification kit.
• Your fnm does not simulate fatigue during qualification .
• Defects in the qualification kit were prepared in house and the kit does not containdefects based on rejects from actual production. Paiticulate defects made in house do not necessai·ily represent defects that would be found from production.
2) Your firm does not have a reject library from which training and familiarization of defects can be studied by new hires or for refresher training.
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically,
Aseptic processing simulations were performed without protocols developed for defining acceptance criteria and worst-case conditions to be simulated. Your firm is cunently performing media fills on the <Redacted B4> syringe size at <Redacted B4> of routine batch size without a documented rationale. According to your firm's CEO, this reduced batch size is used after process validation has been completed and operator qualification is being performed.
In addition, your firm qualified operators utilizing various syringe sizes, <Redacted B4> anq <Redacted B4> without a documented rationale for this bracketing. Your firm's current commercial product uses a <Redacted B4> syringe size with a batch size of the <Redacted B4> syringes. The <Redacted B4> syringe media fill is approximately <Redacted B4> syringes with a shorter fill time and different processing steps than commercial production.
Observation 6
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and written.
Specifically,
Your firm's media fill procedure, SOP-039, was not implemented prior to performing media fills. Your firm's media fill procedure was implemented on 6/12/2024. This procedure does not define acceptance criteria, routine and non-routine interventions to be performed fill volume, or minimum fill time to be achieved for each process to be simulated.
Your firm performed <Redacted B4> media fills prior to implementing any media fill procedure. In addition, no media fill protocols were developed until 11/21/2024. Interventions performed were not documented until protocols were developed. One technician used in routine production has not performed a media fill on the 0.25mL syringe process since procedures were developed.
Observation 7
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
Program, SOP-081 , effective 1/7/2025, states that the routine environmental monitoring procedure governs excm·s10ns and investigations 1ll environmental monitoring. The routine environmental monitoring procedure does not require an investigation into action levels being reached for sample results. Action responses are not defined within the environmental monitoring procedure.
Observation 8
Specifically,
Your firm does not require a second reviewer for environmental monitoring results unless <Redacted B4> colony forming unit (CFU) is found. A single technician reads environmental plate counts and the worksheet with results is later reviewed, however, the physical plates are not verified unless growth is present.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Turbare Manufacturing). That is not a finding beyond this index’s search.
The Turbare Manufacturing pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming semaglutide under the labeler name “Turbare Manufacturing”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 83556-0201 | Semaglutide 1 mg/mL | Semaglutide 1 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 83556-0205 | Semaglutide 5 mg/mL | Semaglutide 5 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.